Success Story: NIW Approved Without RFE! We Helped a Postdoctoral Researcher Secure Success with Premium Processing Service
Client’s Testimonial:
"I had a great experience working with WeGreened on my NIW case. The team was professional, responsive, and very organized throughout the process. They prepared a strong petition package that clearly highlighted my research contributions and proposed endeavor, even without recommendation letters. My case was approved without RFE under premium processing, and I highly recommend them."
On May 16th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Researcher in the Field of Molecular Mechanisms of Neurodegeneration (Approval Notice).
General Field: Molecular Mechanisms of Neurodegeneration
Position at the Time of Case Filing: Postdoctoral Researcher
Country of Origin: South Korea
State of Residence at the Time of Filing: Maryland
Approval Notice Date: May 16th, 2026
Processing Time: 1 month, 10 days (Premium Processing Requested)
Case Summary:
The petition was filed with Direct Premium Processing at the time of filing and was approved in 40 days for our client, a molecular mechanisms of neurodegeneration researcher who holds a Ph.D. Drawing on our extensive experience and a proven track record of over 32,000 successful cases, our expert team prepared a compelling petition on behalf of this researcher.
As an expert in molecular mechanisms of neurodegeneration, the client’s proposed endeavor is to continue investigating conserved, microglia-centered danger-signal mechanisms that drive neuroinflammation across neurodegenerative proteinopathies, with a focus on Parkinson’s spectrum synucleinopathies. We demonstrated that this endeavor has national importance because it addresses the growing burden of neurodegenerative diseases, supports brain-health innovation, and advances translational tools needed for disease monitoring and treatment evaluation.
To strengthen the case, we highlighted objective evidence of the client’s research record and field recognition:
- 11 peer-reviewed journal articles, including 2 first-authored articles, 3 abstracts, including 2 first-authored abstracts, 1 preprint, and 1 first-authored patent
- 373 citations to the client’s published body of work
- At least 14 peer reviews completed to date
The petition did not present these credentials as self-evidently sufficient. Instead, we explained how an adjudicator could interpret them as evidence that the client’s findings had been tested, circulated, and relied upon within the neurodegeneration research community. The petition also contextualized her citation record by showing that 5 of her papers ranked among the top 10% and 1 paper ranked among the top 20% most-cited articles for their respective publication years, demonstrating that her work had drawn notable reliance when compared with similarly situated research.
It has been an honor to support this neurodegeneration researcher throughout this journey, and we extend our sincere best wishes for continued success in advancing biomarker discovery, therapeutic development, and brain-health research in the United States and beyond.